The product lead who would not get the promotion.
Outcome. Internal promo cycle deferred 16 May. Title change to "Group PM" without TC bump on 03 Jun. New offer accepted from a Series-C startup on 06 Aug — week 31, +12% above slate.
Each case below was hashed and posted to the public ledger before the event in question occurred. After settlement the same chart is opened, the prediction is checked against the public record, and the outcome — hit, partial, miss — is appended. We score every sitting we are allowed to publish. Names are anonymised; ledger hashes are not.
Outcome. Internal promo cycle deferred 16 May. Title change to "Group PM" without TC bump on 03 Jun. New offer accepted from a Series-C startup on 06 Aug — week 31, +12% above slate.
Outcome. Met partner Nov 2024 (work conference, not arranged). Engagement 02 Jan 2025. Civil registration 11 Feb 2025. Family ceremonies followed in April — outside the window we sealed, included for completeness.
Outcome. November bloodwork: TSH within range, anti-TPO elevated. Hashimoto's diagnosis confirmed 19 Nov. Treatment commenced. Energy normalised by March 2025 per follow-up.
Outcome. Lead VC paused diligence 19 Mar. Round closed 26 Apr at strategic-led terms — 18% lower pre but with channel partnership. Founder reports the channel deal alone tripled MRR by Q4.
Outcome. Settled 21 Mar 2025 at 58% of plaintiff demand. Opposing counsel was disbarred for unrelated cause six weeks later. Client reports the prediction kept her from a two-year trial.
Outcome. Moved 02 Jul 2024 — to Singapore, not as initially read (we had Mumbai). Direction, climate, hub-type, water-adjacency, timing window all matched. City-level miss.
Outcome. Cycle 4 transfer 12 Aug 2024. Heartbeat confirmation 14 Sep. Healthy delivery May 2025. Clinic's Bayesian model gave the cycle a 41% prior; we read it as the high cycle three sittings prior.
Outcome. Inbound from a strategic on 22 Nov 2023 — not in the curated bank book. Term sheet 18 Dec. Closed 11 Jan 2024 (15 days before Republic Day).
Outcome. Separation announced 12 Mar 2025. Mediation began 21 Mar. Decree finalised 30 Apr — six weeks past the sealed window. Direction and method correct; date by ±6 weeks.
Outcome. CTO resigned 15 Oct 2024 to pursue a personal venture (philanthropic, not financial). New CTO sourced through founder's MIT network — joined 02 Dec. Net positive on velocity within one quarter.
Outcome. Surgery 14 Oct. ICU complication day 19 (sepsis). Discharge 02 Dec. Independent ambulation by 06 Mar 2025. Family confirms the vrat was observed; we make no claim about its mechanism.
Outcome. Out-of-court family settlement 22 May 2024 — at 52% recovery, mediated by elder cousin (correctly identified). Direction, mechanism, season correct; share off by 18 pts.
Every case above ran through the refusal protocol — we do not seal predictions on biological gender of unborn children, on the day of a death, on the outcome of a single legal case where we are not the represented party, or on financial market direction. The 12 cases shown are only those for which the client has signed publication consent. The aggregate hit-rate over 312 sealed sittings (most unpublishable) is consistent with the public sample to within 2 percentage points. Read the method for the full discipline.
Every sitting is sealed before the event. Every reading is hashed and timestamped. We score the work because the work is the only thing worth defending — not the language around it.